ArticleFrontiers in pediatrics2026
Trends in central precocious puberty incidence in Japan during the COVID-19 pandemic.
Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Rising incidence of central precocious puberty in Thailand: a nationwide population-based study before, during, and after the COVID-19 pandemic (2018-2024).Clinical and experimental pediatrics · 2026Article
- Precocious puberty in boys: current insights into etiology, genetic advances, and environmental factors.Frontiers in endocrinology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The incidence of central precocious puberty (CPP) has reportedly increased worldwide during the coronavirus disease 2019 (COVID-19) pandemic; however, multicenter data from Japan remain limited. This study aimed to evaluate temporal changes in the incidence and clinical characteristics of CPP before, during, and after the pandemic. Methods: We conducted a multicenter retrospective observational study across four pediatric endocrinology centers in Kanagawa, Japan. Newly diagnosed CPP cases from 2018 to 2023 were categorized into three periods: pre-pandemic (2018-2019), pandemic (2020-2021), and post-pandemic (2022-2023). Incidence rate ratios (IRRs) were calculated using quasi-Poisson regression, with population size included as an offset. Clinical characteristics-including age at diagnosis, bone age, degree of overweight, and hormone profiles-were compared across periods using the Kruskal-Wallis test. Results: A total of 118 children (94 girls and 24 boys) were diagnosed with CPP during the study period. Among girls, CPP incidence increased significantly during the pandemic compared with the pre-pandemic period [IRR 2.47; 95% confidence interval (CI): 1.29-5.03]. In boys, incidence also increased with a statistically significant IRR; however, the estimate was accompanied by wide confidence intervals owing to the small number of cases. Elevated incidence rates in girls persisted into the post-pandemic period. No significant differences were observed across periods in age at diagnosis, degree of bone age advancement, degree of overweight, or basal and stimulated hormone levels. Nevertheless, the cohort consistently exhibited higher degrees of overweight compared with national reference values. Conclusions: This multicenter study demonstrates a significant increase in CPP incidence among girls during the COVID-19 pandemic in Japan, with sustained elevation in the post-pandemic period. Although clinical characteristics remained largely unchanged, the consistently higher degree of overweight underscores the need to consider lifestyle and environmental factors that may have been exacerbated during the pandemic. Ongoing surveillance and reevaluation of CPP diagnostic criteria may be warranted to address emerging epidemiological trends.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.